GlobeNewsWire · ACR · November 7, 2026

argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis

Get the app for more

Explore stock news, insights and company research.